What is Actiflash intended for?

Actiflash is used to convert your inducible ERT model into a photo-inducible one. Use it if you want to control transcription (using Gal4-UAS) or induce recombination (using Cre-lox) in space and/or time for in-vivo cell tracking experiments and more. Actiflash is for research use only


Features

    1. Wide applicative scope – Technology capitalizing on the versatile use of Tamoxifen-OH for controlling functions of multiple types of proteins.
    2. Simple conditioning – Caged Cyclofen-OH is cell-permeant and can be added either in the external medium or directly injected for conditioning.
    3. Excellent chemical stability – Caged Cyclofen-OH does not generate any basal activation of protein function and it benefits from an excellent temporal resolution upon uncaging.
    4. Favorable wavelength ranges for uncaging – Uncaging requires either UV-A light or a strong IR laser. Visible light is inactive, which facilitates the experiments with biological samples.
    5. Photochemical stability – Caged Cyclofen-OH liberates Cyclofen-OH, which is photostable in contrast to Tamoxifen-OH encountering photodegradation under illumination.


Method of Use:

Calibration of the Actiflash concentration
It is advised to first establish the extent of phenotype sought for as a function of the Tamoxifen-OH concentration. Then the concentration of Actiflash used for sample conditioning is fixed at Tamoxifen-OH concentration causing 100% of the desired phenotype (in general 3-5 μM in cultured cells and zebrafish embryos).

Conditioning protocol
Incubate your samples in a serum-free medium for 90 mins, away from light.

Photoactivation
Illumination of Actiflash may be performed with UV (325-425nm range) light or multiphoton excitation (at 750 and 1064 nm with two- and three-photon excitation, respectively) to release Cyclofen-OH. You can use either benchtop UV lamps or light sources installed on microscopes.

The calibration of the photoactivation
The objective is to provide enough photons to exhaust the conversion of the Actiflash but without generating detrimental side-effects on the biological sample. Simply analyze the phenotype recovery with decreasing illumination duration. Then determine the shortest illumination duration leading to 100% uncaging of Actiflash.


5 Key Conditions of Success

  1. Actiflash is provided as a powder. Resuspend it with DMSO (warning: no water).
  2. Only unfreeze the aliquots you need for your experiment.
  3. Carefully calibrate the photoactivation of Actiflash (concentration for conditioning, power of the light source, geometry and duration of illumination). Then always work under the same conditions.
  4. Use a serum-free medium during the incubation step of the cell lines.
  5. In the dark, just before photoactivation, wash your samples (unnecessary for two-photon laser experiments).


For more information about this product or any others from the Microscopy line, contact us here.

Eagle Biosciences, Inc. is excited to partner with Idylle to bring you an exciting new variety of products!

Idylle is a unique company that is based in France. Their facilities include a state of the art tech transfer platform that works to bring innovation into life science workflows. They produce some of the most innovative R&D tools, side by side with researchers who design, test, and use them. Their products are easy to handle research tools that have been approved by the scientific community using Idylle’s unique ‘Test Programs’. These Test Programs are a four-week trial that allows researchers to test the products in their workflow and share their feedback.

We will be offering some of these products in a microscopy line that is intended to help improve your imaging needs. Check out the items below, and follow along in the upcoming weeks as we take a deep dive into each item.


Microscopy Products

Actiflash – Stable Tamoxifen-like photoactivable inducer.

Chitozen – The 1st functionalized microscope coverslip to image live bacteria

Everspark – Ready to use super-resolution microscopy buffer.

Stampwell – A family of stamps to democratise the 3D culture.

Stencell – The PDMS no-brainer solution for all micro-volume experiments, anywhere.


If you have a question about any of these products, or any of our other offerings, contact us here.


Eagle Biosciences, Inc. is continuing to work with BPM Biotech in the support the Fetuin A (PTM) ELISA (DNlite-DKD)!


About Fetuin A (PTM) ELISA

This Fetuin A (PTM) ELISA (DNLite-DKD) measures a unique biomarker that can have great impact on those with diabetic kidney disease (DKD). The Fetuin A post translation modifications (PRM) measured in this assay was identified in a large-scale profiling of urinary proteomics. This new biomarker can help predict the kidney condition of diabetes patients, months to years in advanced. This urine test can help predict kidney decline or complications and potentially improve a patient with diabetic kidney disease quality of care.


Check out the flyer below for a comprehensive look at this unique test!


Other Reference Materials

Instructions for Use
Acute Kidney Disease in the Outpatient Setting


If you have any questions about this product or any of our other offerings, contact us here.

Endostatin Biomarker Spotlight

The mature form of brain natriuretic peptide (BNP) is formed from the BNP (1-108) precursor and is secreted predominantly by the cardiac ventricles. Circulating forms of BNP include BNP-32 (77-108), a high molecular weight BNP which has not been well characterized and and the nt-proBNP (1-76). The BNP fragment is typically measured as a proxy for BNP because of its longer half-life. Recent research suggests that natriuretic peptides are important protectors against fluid overload and high blood pressure. BNP has also been implicated as a valuable marker in assessing cardiac risk.

The natriuretic peptides are members of a family of structurally similar but genetically distinct peptide hormones, consisting of atrial-, brain-, and C-type (ANP, BNP, and CNP, respectively). ANP and BNP preferentially bind to a membrane-bound guanylyl cyclase (GC) receptor called GC-A or NPR1, whereas CNP is the physiological ligand for GC-B (NPR2). The natriuretic peptides play an important role in the regulation of cardiovascular and renal homeostasis and in the regulation of fatty acid metabolism and body weight.
BNP is mainly expressed by ventricular myocardium in response to volume overload and increased filling pressure. BNP has a cleavable signal sequence. Mature BNP consists of 108 amino acids (proBNP or BNP-108), and undergoes cleavage resulting in physiologically active BNP-32 and additional C-terminal fragments along with a physiologically inactive N-terminal peptide comprising amino acids 1-76, which is further degraded proteolytically. BNP fragments in the circulation are therefore very heterogenous.
BNP has a key role in cardiovascular homeostasis with biological actions including natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. A high concentration of BNP in the bloodstream is indicative of heart failure. The discovery of natriuretic peptides identified an endocrine system that contributes to diuresis and vascular tone. The biology, biochemistry and the pathophysiological role of natriuretic peptides are described in several reviews.


NT-proBNP ELISA Assay Kit

  • Convenient
  • Reliable
  • High Quality Guaranteed

If you have any questions about this item or any of our other offerings contact us here.

EagleBio Visits AACC in Atlanta Georgia

Eagle Biosciences will be at AACC in Chicago, Illinois!

This year AACC is in Chicago at the McCormick Place Convention Center, Sunday July 24th – Thursday July 28th. We will be at booth #315! Come by to learn about the GA-Map Dybiosis Test Lx and more assays that could help you with your microbiome or other research! We will be there to answer any questions you may have, or stop and say hi! We love seeing our customers!


Product Highlights

GA-Map Dysbiosis Test Lx: The first and only standardized solution for microbiome profiling! The GA-Map Dysbiosis Test Lx is a simple multiplex stool assay that maps the intestinal microbiota profile for a selected set of bacteria. The GA-map® platform uses probes that target variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by Professor Knut Rudi (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine dysbiosis level in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.

GA-map® Dysbiosis Test Lx Procedure Quick Guide

GA-map Dysbiosis Test


If you have any other questions about these products or our other offerings, contact us here.


Intracerebral hemorrhage (ICH) is caused by bleeding within the brain. Very few circulating biomarkers are known to be associated with the risk of ICH. Fibroblast growth factor 23 is a bone-derived protein hormone associated with mortality in patients with heart failure. A recent nested case–control study showed that Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage: Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage. Svensson EH, Söderholm M. Eur J Neurol. 2022 Jan;29(1):114-120. doi: 10.1111/ene.15060. PMID: 34379844.


Abstract

Background and purpose: Fibroblast growth factor 23 is an osteogenic hormone associated with chronic kidney disease and is an emerging risk factor for several cardiovascular diseases. The association of Fibroblast growth factor 23 (FGF23) with stroke is unclear. The aim of this study was to investigate the association of FGF23 with incident intracerebral hemorrhage (ICH).

Methods: This was a nested case-control study of 220 ICH cases and 244 age- and sex-matched controls from the population-based Malmö Diet and Cancer Study (n = 28,449). Incident ICH cases were ascertained using national registers and classified by bleeding location. Logistic regression was used to study the association of plasma levels of FGF23 with incident ICH, adjusting for potential ICH risk factors. Subgroup analyses were performed for lobar and non-lobar ICH, fatal ICH, ICH with large volume and ICH with poor functional outcome, respectively.

Results: Higher FGF23 levels at baseline were significantly associated with incident ICH. After multivariable adjustment, the odds ratio for the association with all ICH was 1.84 (95% confidence interval [CI] 1.25-2.71, p = 0.002) per doubling of FGF23 concentration. For lobar and non-lobar ICH, odds ratios were 1.73 (95% CI 1.04-2.87, p = 0.035) and 2.13 (95% CI 1.32-3.45, p = 0.002), respectively. FGF23 was also significantly associated with fatal ICH, ICH with large volume and ICH with poor functional outcome.

Conclusions: Higher FGF23 was associated with incident ICH in this nested case-control study. Further studies are required to explore whether the association is causal.


Eagle Biosciences’ FGF23 kits listed below:

FGF23 C-Terminal ELISA Assay Kit
MedFrontier Intact FGF23 Assay


If you have any questions about this items or any of our other offerings, contact us here.

Recent GA-Map Dysbiosis Test Lx Publications
Check out the most recent publications featuring the GA-Map Dysbiosis Test Lx! These studies used the GA-Map Dysbiosis Test Lx to help determine how the gut microbiota takes part in various diseases such as IBS and axial spondyloarthritis. Find them below:


Irritable bowel syndrome patients who are not likely to respond tofecal microbiota transplantation.

Efficacy and Acceptability of Dietary Therapies in NonConstipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet andthe Gluten-Free Diet.

Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.


Principle of Analysis

The GA-map® Dysbiosis Test Lx v2 is a test that maps the intestinal microbiota profile for a selected set of bacteria. The GA-map® platform uses probes that target variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by Professor Knut Rudi (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine dysbiosis level in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.


If you’re looking for more publications featuring the GA-Map Dysbiosis Test Lx, find them here. If you have any questions about this test or any of our other offerings contact us here. 

Fetuin A (PTM) ELISA New Product Announcement

Eagle Biosciences is excited to partner with BPM and support the Fetuin A (PTM) ELISA (DNlite-DKD)!

About Fetuin A (PTM)

The unique Fetuin A post translation modifications measured in this assay were identified in a large-scale profiling of urinary proteomics. This new biomarker can help predict the kidney condition of diabetes patients, months to years in advanced. This urine test can help predict kidney decline or complications and potentially improve a patient with diabetic kidney disease quality of care.

Principle of the Fetuin A (PTM) ELISA

The Fetuin A (PTM) ELISA (unique Fetuin-A with specific post translational modification (PTM) for Diabetic Kidney Disease (DKD)) is a competitive immunoassay. In this Fetuin A (PTM) ELISA, calibrators or unknown urine samples are mixed with anti-unique PTM Fetuin-A monoclonal antibody (mAb), and then incubated in a microplate pre-bounded with unique PTM Fetuin-A. The monoclonal antibody recognizes unique PTM Fetuin-A in calibrators or unknown samples under competition in microplate wells. After an incubation, an Horseradish Peroxide (HRP) conjugated secondary antibody is added, followed by an incubation with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate. Their relative reactivity is determined by absorbance measurement at 450 nanometers (nm) and plotted by comparison with a predetermined unique PTM Fetuin-A calibration curve.

Benefits of the Assay

    • Fewer Steps
    • Shorter processing times – ever for high-throughput samples

If you have any questions about this kit or any of our other offerings, contact us here.

TDM Assay Highlight
Eagle Biosciences is proud to highlight our extensive range of Therapeutic Drug Monitoring (TDM) Assays!

Why use TDM Assays?

TDM Assays for biosimilars and biologics are developed primarily for the studies and development of drugs and vaccines in specific therapeutics and therapeutic pathways. They are utilized by pharmaceutical and biopharmaceutical companies, as well as universities and other researchers to aide in a wide variety of research fields.

About TDM Assays

It has long been acknowledged that data on different drug and target species (e.g., free vs total levels of drug target as two possible biomarkers) may satisfy different needs. Depending on the information required for decision-making, the data required and hence the selection of assay (free, total or both) may differ at each phase of drug development.

Free drug levels reflect the availability of the active drug, while the total or bound drug complex is of importance when checking for efficacy or dynamic interactions of the drug, and for other PK/PD assessments. Thus, it is important to understand the information needed at different stages of drug development.

We offer a wide range of products to measure free and partially bound drug, as well as total drug (free, bound, partially bound), and the bound drug complex.

And we’ll be expanding our extensive line in the future!


If you have any questions about our TDM Assay Kits or our other offerings, contact us here.

GA-map Dysbiosis Test

Understanding the Microbiome with Pioneering Research at Genetic Analysis

Anita Jusnes and Christin Casén of Genetic Analysis AS were recently featured on Dr. Ruscio Radio! They discuss with Dr. Ruscio the GA-Map Dysbiosis Test Lx, the only research dysbiosis index for the gut. The conversation covers topics including but not limited to, how the test came to be, the methodology behind the results, how the test has been validated, and how it can be used to distinguish healthy controls from other samples.

Find the full episode and transcript here.


About the GA-map Dysbiosis Test

The human microbiome market is accelerating both in terms of evidence-based research and pharma products launched. The market’s need for a validated microbiome test is growing. Genetic Analysis AS is at the forefront of this development with the GA-map Dysbiosis Test. The unique, GA-map® Dysbiosis Test, detects and characterizes imbalance in the gut microbiota (dysbiosis) in human fecal samples. All pre-processing of the data is done by the GA-map® Dysbiosis Test analyze software. Reports are automatically generated on the dysbiosis index (DI) and the bacteria abundance. The DI can be customized to your needs. Based on a deviation from a normal reference population, a measure of bacteria abundances and deviations to the references are calculated. The results are presented in an easy to interpret report form, containing the 48 preselected bacteria markers.

Additionally, Genetic Analysis has developed a fecal COVID-19 test that is performed on the same GA-map platform and is an important research tool in the analysis of an individual’s COVID-19 status.


If you have any questions about the GA-map Dysbiosis Test Lx or any of our other offerings, contact us here.